Eric Jonasch, MD
Enriched profileProfessor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center
Eric Jonasch is Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 613 publications with 23,264 citations (h-index 68); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 31 Aug 2026
Eric Jonasch, M.D., is Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 613 publications with 23,264 citations (h-index 68), centered on Renal cell carcinoma treatment, Renal and related cancers, Cancer Genomics and Diagnostics. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 17 companies, 1 NIH-funded awards (2011–2011).
- Most recent indexed publication: 2026 · Neuro-oncology advances
- Top research focus: Renal cell carcinoma treatment
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 208.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Aug 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Sponsor: M.D. Anderson Cancer Center
- Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Sponsor: M.D. Anderson Cancer Center
- Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 31 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202538 payments$54,188openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments$36,934openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.8%Kinase inhibitor45.9%Cabometyx43%Lenvima33%Everolimus18%Sunitinib Malate6%Part D<11 patientsHypoxia-inducible Factor Inhibitor10.8%Welireg100%Part D<11 patientsNervous system
14.7%Benzodiazepine6.4%Alprazolam50%Diazepam50%Part D<11 patientsCentral Nervous System Stimulant2.9%Methylphenidate Hcl100%Part D<11 patientsRespiratory
9.1%Opioid Agonist9.1%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 31 Aug 2026
1 NIH research award on record, funded 2011–2011 per NIH RePORTER. The latest:
- Biannual von Hippel Lindau Family Alliance Medical Meeting
University of Tx Md Anderson Can Ctr
FY2011$8,000R13CA165693
Congress activity
Updated 31 Aug 2026
173 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 31 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.
Journal for immunotherapy of cancer
Article2026 - Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
CA: a cancer journal for clinicians
Article2026
Most-cited works
by citation count (OpenAlex)- 01Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Article6,014 citations2016
- 02High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer typesArticle1,069 citations2021
- 03Clear cell renal cell carcinoma ontogeny and mechanisms of lethalityArticle699 citations2020
- 04Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle664 citations2022
- 05Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaArticle395 citations2015
Network
Updated 31 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 31 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eric-jonasch-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/eric-jonasch-aa418412
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
sciprofiles.com/profile/1953450
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sciprofiles.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/TheASCOPost/videos/eric-jonasch-md-on-kidney-cancer-a-year-in-review/414919815923019
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
ascopost.com/archive/meetings/2015-nccn-annual-conference/eric-jonasch-md-on-kidney-cancer-treatment-options
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
ascopost.com/videos/nccn-annual-conference-2019/eric-jonasch-on-kidney-cancer-a-year-in-review
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- M.D. (MDCM)
McGill University Faculty of Medicine, Montreal (1992), corroborates NPI credential 'M.D.'
1992verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Director
VHL (Von Hippel-Lindau) Clinical Center, MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Co-Director
MD Anderson Kidney Cancer Research Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Principal Investigator
Department of Defense Kidney Cancer Research Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancerconsortium.org ↗
Media & interviews
press, podcasts and appearances- VJOncology video interview
ASCO GU 2025: "Kidney cancer at ASCO GU 2025: CheckMate 9ER & LITESPARK-011"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center